AUTHORS
Michael Loschi, MD, PhD, Jean-Christophe Ianotto, MD, PhD, HDR2, Jérôme Rey3, Florence Pasquier, MD, PhD4, Sophie Vantyghem, MD5, Steve Knapper6, Andrew Innes, MD PhD7, Stefan Wickenhauser, MD8, Jennifer O'Sullivan, MB Bch BAO9, Jean-Jacques Kiladjian10, Srinivasan Narayanan11, Sebastian Francis12, Jose Miguel Torregrosa Diaz, MD13, Carol MacLean, PhD14, Karen Smith, MD, PhD15, Maureen Higgins, PhD16, Philip Beer, MD, PhD17, Adam Mead, MBBChir18
AFFILIATIONS
1 CHU Nice, Nice, France
2 CHU Brest, Brest, France
3 Institut Paoli-Calmette, Marseille, France
4 Institut Gustave Roussy, Paris, France
5 CHU Nantes, Nantes, France
6 Cardiff University Hospital, Cardiff, United Kingdom
7 Imperial College, London, United Kingdom
8 CHU Nimes, Nimes, France
9 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
10 APHP Saint louis, Paris, United Kingdom
11 Southampton Hospital, Southampton, United Kingdom
12 Sheffield Teaching Hospital NHS Trust, Sheffield, United Kingdom
13 CHU Poitiers, CHU, France
14 Step Pharma, Saint-Genis-Pouilly, France
15 Step Pharma, Saint-Genis-Pouilly, France
16 Step Pharma, Saint-Genis-Pouilly, France
17 Step Pharma, Saint-Genis-Pouilly, France
18 University of Oxford, Oxford, United Kingdom
ABSTRACT
Background: Effective, well-tolerated therapies for essential thrombocythemia (ET) remain limited, particularly for those failing first line hydroxyurea (hydroxycarbamide). Megakaryocyte generation depends on CTPS1, the rate-limiting enzyme in de novo pyrimidine synthesis. Dencatistat (STP938) is a highly selective oral CTPS1 inhibitor. Preclinical studies with dencatistat demonstrate reduced megakaryocyte generation from progenitor cells and decreased release of inflammatory cytokines (IL-8, TNFα) from activated T cells. In oncology clinical trials, dencatistat produced dose-dependent platelet reductions without cytopenias in other lineages, consistent with selective CTPS1 inhibition. The VECTRA study (NCT06786234) is an ongoing phase 2 trial evaluating dencatistat in high-risk ET. The study is currently recruiting in France and the UK, with additional sites opening in Spain, Italy and the USA.
Methods: Adults with high-risk ET resistant to or intolerant of hydroxyurea with platelet count ≥600 ×10?/L are eligible for enrollment. High-risk features include age ≥60 years, platelet count >1500 ×10?/L, prior thrombosis/hemorrhage, microvascular symptoms, or diabetes/hypertension requiring therapy. Participants (pts) received once daily oral dencatistat with individualized dose titration to achieve platelet control. Primary endpoints are efficacy, safety, and tolerability. Secondary endpoints include durability of hematologic response and rates of thrombosis, hemorrhage, and disease transformation. Exploratory endpoints include symptom burden (MPN-SAF-18), molecular response, spleen volume, and pharmacokinetics.
Results: As of July 21, 2026, 14 pts were enrolled; median (range) age 74 years (40–89); baseline platelet count 879 ×10?/L (520–1911); prior therapies 2 (1–3); 50% female. All major ET genotypes were represented (JAK2 36%, CALR 36%, MPL 14%, triple-negative 14%). Median time on treatment was 15 weeks (1–29). Twelve pts (86%) experienced treatment emergent adverse events, most commonly anemia (50%), nausea (29%), alopecia (14%), bruising (14%), fatigue (14%), and thrombocytopenia (14%). Most events were grade 1/2; one pt had grade 3 anemia. Of the 7 pts reporting anemia on study, 5 were anemic at baseline. Nine pts (64%) had treatment related adverse events, predominantly anemia (29%) and nausea (29%). There were no episodes of neutropenia reported. Three pts discontinued (one due to a pre-existing condition, two by choice). Among 12 evaluable pts, 10 (83%) achieved platelet normalization (150–400 ×10?/L), and all achieved platelets <600 ×10?/L. Median maximal platelet reduction was 76% (22–86%). No thromboembolic events or disease transformation has occurred. Durability data are maturing.
Conclusions: Dencatistat, a first-in-class oral CTPS1 inhibitor, demonstrates consistent and clinically meaningful platelet control with a favorable tolerability profile in high-risk ET. Enrollment is ongoing toward a target of 50 pts. Maturing data, including durability of response, variant allele fraction, plasma IL-8 levels, and symptom burden, will be presented.
DISCLOSURES
Michael Loschi, MD, PhD: novartis - Honoraria; jazz - Honoraria; Menarini Stemline - Honoraria; Abbvie - Honoraria; AOP Orp - Honoraria; Gilead - Honoraria; Bristol Myers Squibb - Honoraria; GSK - Honoraria; Gilead - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); sumitomo - Consultancy (Includes expert testimony); MaaT pharma - Consultancy (Includes expert testimony); novartis - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Keros - Consultancy (Includes expert testimony)